<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SECTRAL - acebutolol hydrochloride capsule </strong><br>Promius Pharma, LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sectral (acebutolol HCl) is a selective, hydrophilic
							beta-adrenoreceptor blocking agent with mild intrinsic sympathomimetic
							activity for use in treating patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and ventricular
							<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. It is marketed in capsule form for oral administration.
							Sectral capsules are provided in two dosage strengths which contain 200
							or 400 mg of acebutolol as the hydrochloride salt. The inactive
							ingredients present are D&amp;C Red 22, FD&amp;C Blue 1,
							FD&amp;C Yellow 6, gelatin, povidone, starch, stearic acid, and
							titanium dioxide. The 200 mg dosage strength also contains D&amp;C
							Red 28 and the 400 mg dosage strength also contains FD&amp;C Red 40.</p>
<p>Acebutolol HCl has the following structural formula:<br><img alt="Image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7eee95bf-0452-4d6e-9712-33403768695a&amp;name=sectral-structure.jpg"></p>
<p>Acebutolol HCl is a white or slightly off-white powder freely
							soluble in water, and less soluble in alcohol. Chemically it is defined
							as the hydrochloride salt of (±)N-[3-Acetyl-4-[2-
							hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl] butanamide. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"> Sectral is a cardioselective, β-adrenoreceptor blocking
							agent, which possesses mild intrinsic sympathomimetic activity (ISA) in
							its therapeutically effective dose range. </p>
<div class="Section" data-sectionCode="43681-6">
<a name="Pharmacodynamics"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First"> β<span class="Sub">1</span>-cardioselectivity has been
									demonstrated in experimental animal studies. In anesthetized
									dogs and cats, Sectral is more potent in antagonizing
									isoproterenol-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (β<span class="Sub">1</span>) than
									in antagonizing isoproterenol-induced <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>
										(β<span class="Sub">2</span>).In guinea pigs and cats, it is more
									potent in antagonizing this <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> than in antagonizing
									isoproterenol- induced bronchodilatation
									(β<span class="Sub">2</span>). ISA of Sectral has been demonstrated
									in catecholamine-depleted rats by <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> induced by
									intravenous administration of this agent. A membrane-stabilizing
									effect has been detected in animals, but only with high
									concentrations of Sectral. </p>
<p>Clinical studies have demonstrated
									β<span class="Sub">1</span>-blocking activity at the recommended
									doses by: a) reduction in the resting heart rate and decrease in
									exercise-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; b) reduction in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> at
									rest and after exercise; c) reduction of systolic and diastolic
									blood pressures at rest and postexercise; d) inhibition of
									isoproterenol-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. </p>
<p> The β<span class="Sub">1</span>-selectivity of Sectral has
									also been demonstrated on the basis of the following vascular
									and bronchial effects: </p>
<p>Vascular Effects: Sectral has less antagonistic effects
									on peripheral vascular β<span class="Sub">2</span>-receptors at rest
									and after epinephrine stimulation than nonselective
									β-antagonists. </p>
<p>Bronchial Effects: In single-dose studies in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span>
									examining effects of various beta-blockers on pulmonary
									function, low doses of acebutolol produce less evidence of
									<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> and less reduction of beta<span class="Sub">2</span>
									agonist, bronchodilating effects, than nonselective agents like
									propranolol but more than atenolol. </p>
<p> ISA has been observed with Sectral in man, as shown by a
									slightly smaller (about 3 beats per minute) decrease in resting
									heart rate when compared to equivalent β-blocking doses
									of propranolol, metoprolol or atenolol. Chronic therapy with
									Sectral induced no significant alteration in the blood lipid
									profile. </p>
<p> Sectral has been shown to delay AV conduction time and
									to increase the refractoriness of the AV node without
									significantly affecting sinus node recovery time, atrial
									refractory period, or the HV conduction time. The
									membrane-stabilizing effect of Sectral is not manifest at the
									doses used clinically. </p>
<p> Significant reductions in resting and exercise heart
									rates and systolic blood pressures have been observed 1.5 hours
									after Sectral administration with maximal effects occurring
									between 3 and 8 hours postdosing in normal volunteers. Sectral
									has demonstrated a significant effect on exercise-induced
									<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> 24 to 30 hours after drug administration. </p>
<p>There are significant correlations between plasma levels
									of acebutolol and both the reduction in resting heart rate and
									the percent of β-blockade of exercise-induced
									<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. </p>
<p>The antihypertensive effect of Sectral has been shown in
									double-blind controlled studies to be superior to placebo and
									similar to propranolol and hydrochlorothiazide. In addition,
									patients responding to Sectral administered twice daily had a
									similar response whether the dosage regimen was changed to once
									daily administration or continued on a b.i.d. regimen. Most
									patients responded to 400 to 800 mg per day in divided doses. </p>
<p> The antiarrhythmic effect of Sectral was compared with
									placebo, propranolol, and quinidine. Compared with placebo,
									Sectral significantly reduced mean total ventricular ectopic
									beats (VEB), paired VEB, multiform VEB, R-on-T beats, and
									<span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (VT). Both Sectral and propranolol
									significantly reduced mean total and paired VEB and VT. Sectral
									and quinidine significantly reduced resting total and complex
									VEB; the antiarrhythmic efficacy of Sectral was also observed
									during exercise. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="PKandMetabolism"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First"> Sectral is well absorbed from the GI tract. It is
									subject to extensive first-pass hepatic biotransformation, with
									an absolute bioavailability of approximately 40% for the parent
									compound. The major metabolite, an N-acetyl derivative
									(diacetolol), is pharmacologically active. This metabolite is
									equipotent to Sectral and in cats is more cardioselective than
									Sectral; therefore, this first-pass phenomenon does not
									attenuate the therapeutic effect of Sectral. Food intake does
									not have a significant effect on the area under the plasma
									concentration-time curve (AUC) of Sectral although the rate of
									absorption and peak concentration decreased slightly. </p>
<p> The plasma elimination half-life of Sectral is
									approximately 3 to 4 hours, while that of its metabolite,
									diacetolol, is 8 to 13 hours. The time to reach peak
									concentration for Sectral is 2.5 hours and for diacetolol, after
									oral administration of Sectral, 3.5 hours. </p>
<p> Within the single oral dose range of 200 to 400 mg, the
									kinetics are dose proportional. However, this linearity is not
									seen at higher doses, probably due to saturation of hepatic
									biotransformation sites. In addition, after multiple dosing the
									lack of linearity is also seen by AUC increases of approximately
									100% as compared to single oral dosing. Elimination via renal
									excretion is approximately 30% to 40% and by nonrenal mechanisms
									50% to 60%, which includes excretion into the bile and direct
									passage through the intestinal wall. </p>
<p> Sectral has a low binding affinity for plasma proteins
									(about 26%). Sectral and its metabolite, diacetolol, are
									relatively hydrophilic and, therefore, only minimal quantities
									have been detected in the cerebrospinal fluid (CSF). </p>
<p> Drug interaction studies with tolbutamide and warfarin
									indicated no influence on the therapeutic effects of these
									compounds. Digoxin and hydrochlorothiazide plasma levels were
									not affected by concomitant Sectral administration. The kinetics
									of Sectral were not significantly altered by concomitant
									administration of hydrochlorothiazide, hydralazine,
									sulfinpyrazone, or oral contraceptives. </p>
<p> In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, there is no effect on
									the elimination half-life of Sectral, but there is decreased
									elimination of the metabolite, diacetolol, resulting in a two-
									to three-fold increase in its half-life. For this reason, the
									drug should be administered with caution in patients with renal
									insufficiency (see <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>). Sectral and its major metabolite are dialyzable. </p>
<p>Sectral crosses the placental barrier and is secreted in
									breast milk. </p>
<p>In geriatric patients, the bioavailability of Sectral and
									its metabolite is increased, approximately two-fold, probably
									due to decreases in the first-pass metabolism and renal function
									in the elderly. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section">
<a name="<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>"></a><a name="section-3.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First"> Sectral is indicated for the management of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>
									in adults. It may be used alone or in combination with other
									antihypertensive agents, especially thiazide-type diuretics.
								</p>
</div>
<div class="Section">
<a name="section-3.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmias</span></h2>
<p class="First"> Sectral is indicated in the management of ventricular
									<span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span>; it reduces the total number of <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span>,
									as well as the number of paired and multiform ventricular
									ectopic beats, and R-on-T beats. </p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"> Sectral is contraindicated in: 1) persistently severe
							<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; 2) second- and third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>; 3) overt cardiac
							failure; and 4) <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.) </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section">
<a name="CardiacFailure"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First"> Sympathetic stimulation may be essential for support of
									the circulation in individuals with diminished myocardial
									contractility, and its inhibition by β-adrenergic
									receptor blockade may precipitate more severe failure. Although
									β-blockers should be avoided in overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>,
									Sectral can be used with caution in patients with a history of
									<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> who are controlled with digitalis and/or
									diuretics. Both digitalis and Sectral impair AV conduction. If
									<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> persists, therapy with Sectral should be
									withdrawn. </p>
</div>
<div class="Section">
<a name="section-5.2"></a><p></p>
<h2>In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First"> In patients with aortic or <span class="product-label-link" type="condition" conceptid="319843" conceptname="Mitral valve disorder">mitral valve disease</span> or
									compromised left ventricular function, continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of
									the myocardium with β-blocking agents over a period of
									time may lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first signs of failure,
									patients should be digitalized and/or be given a diuretic and
									the response observed closely. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> continues
									despite adequate digitalization and/or diuretic, Sectral therapy
									should be withdrawn. </p>
</div>
<div class="Section">
<a name="section-5.3"></a><p></p>
<h2>Exacerbation of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span> Following Abrupt
								Withdrawal</h2>
<p class="First"> Following abrupt cessation of therapy with certain
									β-blocking agents in patients with coronary artery
									disease, exacerbation of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and, in some cases,
									<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported. Therefore,
									such patients should be cautioned against interruption of
									therapy without a physician’s advice. Even in the absence of
									overt <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, when discontinuation of Sectral is
									planned, the patient should be carefully observed, and should be
									advised to limit physical activity to a minimum while Sectral is
									gradually withdrawn over a period of about two weeks. (If
									therapy with an alternative β-blocker is desired, the
									patient may be transferred directly to comparable doses of
									another agent without interruption of β-blocking
									therapy.) If an exacerbation of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> occurs,
									antianginal therapy should be restarted immediately in full
									doses and the patient hospitalized until his condition
									stabilizes. </p>
</div>
<div class="Section">
<a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral Vascular Disease</span></h2>
<p class="First"> Treatment with β-antagonists reduces cardiac
									output and can precipitate or aggravate the symptoms of arterial
									insufficiency in patients with peripheral or mesenteric vascular
									disease. Caution should be exercised with such patients, and
									they should be observed closely for evidence of progression of
									arterial obstruction. </p>
</div>
<div class="Section">
<a name="section-5.5"></a><p></p>
<h2>Bronchospastic Disease</h2>
<p class="First"> PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL,
									NOT RECEIVE A β-BLOCKER. Because of its relative
										β<span class="Sub">1</span>-selectivity, however, low doses of
									Sectral may be used with caution in patients with bronchospastic
									disease who do not respond to, or who cannot tolerate,
									alternative treatment. Since β<span class="Sub">1</span>-selectivity
									is not absolute and is dose-dependent, the lowest possible dose
									of Sectral should be used initially, preferably in divided doses
									to avoid the higher plasma levels associated with the longer
									dose-interval. A bronchodilator, such as theophylline or a
										β<span class="Sub">2</span>- stimulant, should be made available
									in advance with instructions concerning its use. </p>
</div>
<div class="Section">
<a name="section-5.6"></a><p></p>
<h2>Anesthesia and Major Surgery</h2>
<p class="First"> The necessity, or desirability, of withdrawal of a -
									blocking therapy prior to major surgery is controversial.
									-adrenergic receptor blockade impairs the ability of the heart
									to respond to -adrenergically mediated reflex stimuli. While
									this might be of benefit in preventing arrhythmic response, the
									risk of excessive myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> during general
									anesthesia may be enhanced and difficulty in restarting and
									maintaining the heart beat has been reported with beta-blockers.
									If treatment is continued, particular care should be taken when
									using anesthetic agents which depress the myocardium, such as
									ether, cyclopropane, and trichlorethylene, and it is prudent to
									use the lowest possible dose of Sectral. Sectral, like other
									-blockers, is a competitive inhibitor of -receptor agonists, and
									its effect on the heart can be reversed by cautious
									administration of such agents (e.g., dobutamine or
									isoproterenol—see <span class="Bold"><a href="#Overdosage">OVERDOSAGE</a></span>). Manifestations of excessive vagal tone (e.g.,
									profound <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) may be corrected </p>
</div>
<div class="Section">
<a name="section-5.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First"> β-blockers may potentiate insulin-induced
									<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and mask some of its manifestations such as
									<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; however, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> are usually not
									significantly affected. Diabetic patients should be warned of
									the possibility of masked <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. </p>
</div>
<div class="Section">
<a name="section-5.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First"> β-adrenergic blockade may mask certain clinical
									signs (<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Abrupt withdrawal of
									β-blockade may precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>; therefore,
									patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> from whom
									Sectral therapy is to be withdrawn should be monitored closely.
								</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2></h2>
<div class="Section">
<a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Risk of Anaphylactic
										Reaction</span></h3>
<p class="First"> While taking beta-blockers, patients with a
											history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of
											allergens may be more reactive to repeated challenge,
											either accidental, diagnostic, or therapeutic. Such
											patients may be unresponsive to the usual doses of
											epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.
										</p>
</div>
<div class="Section">
<a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Impaired Renal or Hepatic
										Function</span></h3>
<p class="First"> Studies on the effect of acebutolol in patients
											with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have not been performed in the
											U.S. Foreign published experience shows that acebutolol
											has been used successfully in chronic renal
											insufficiency. Acebutolol is excreted through the GI
											tract, but the active metabolite, diacetolol, is
											eliminated predominantly by the kidney. There is a
											linear relationship between renal clearance of
											diacetolol and creatinine clearance. Therefore, the
											daily dose of acebutolol should be reduced by 50% when
											the creatinine clearance is less than 50 mL/min and by
											75% when it is less than 25 mL/min. Sectral should be
											used cautiously in patients with impaired hepatic
											function. </p>
<p> Sectral has been used successfully and without
											problems in elderly patients in the U.S. clinical trials
											without specific adjustment of dosage. However, elderly
											patients may require lower maintenance doses because the
											bioavailability of both Sectral and its metabolite are
											approximately doubled in this age group. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.1.3"></a><p></p>
<h3><span class="Bold">Information for Patients</span></h3>
<p class="First"> Patients, especially those with evidence of
											<span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, should be warned against
											interruption or discontinuation of Sectral therapy
											without a physician’s supervision. Although cardiac
											failure rarely occurs in properly selected patients,
											those being treated with β-adrenergic blocking
											agents should be advised to consult a physician if they
											develop signs or symptoms suggestive of impending CHF,
											or unexplained respiratory symptoms. </p>
<p> Patients should also be warned of possible
											severe hypertensive reactions from concomitant use of
											α-adrenergic stimulants, such as the nasal
											decongestants commonly used in OTC <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> preparations and
											nasal drops. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7"></a><p></p>
<h1><span class="Bold">Clinical Laboratory Findings</span></h1>
<p class="First"> Sectral<span class="Sup">®</span>, like other β-blockers,
							has been associated with the development of antinuclear antibodies
							(ANA). In prospective clinical trials, patients receiving Sectral had a
							dose-dependent increase in the development of positive ANA titers, and
							the overall incidence was higher than that observed with propranolol.
							Symptoms (generally persistent <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>) related to this
							laboratory abnormality were infrequent (less than 1% with both drugs).
							Symptoms and ANA titers were reversible upon discontinuation of
							treatment. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">Drug Interactions</span>:</h1>
<p class="First"> Catecholamine-depleting drugs, such as reserpine, may have an
							additive effect when given with β-blocking agents. Patients
							treated with Sectral plus catecholamine depletors should, therefore, be
							observed closely for evidence of marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> which
							may present as <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>/<span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">presyncope</span>, or orthostatic changes in
							blood pressure without compensatory <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Exaggerated
							hypertensive responses have been reported from the combined use of
							β-adrenergic antagonists and α-adrenergic stimulants,
							including those contained in proprietary <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> remedies and
							vasoconstrictive nasal drops. Patients receiving β-blockers
							should be warned of this potential hazard. </p>
<p> Blunting of the antihypertensive effect of beta-adrenoceptor
							blocking agents by nonsteroidal anti-inflammatory drugs has been
							reported.</p>
<p> No significant interactions with digoxin, hydrochlorothiazide,
							hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or
							warfarin have been observed. </p>
<p> Both digitalis glycosides and beta-blockers slow
							atrioventricular conduction and decrease heart rate. Concomitant use can
							increase the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">Carcinogenesis, Mutagenesis, Impairment of
							Fertility</span>:</h1>
<p class="First"> Chronic oral toxicity studies in rats and mice, employing dose
							levels as high as 300 mg/kg/day, which is equivalent to 15 times the
							maximum recommended (60 kg) human dose, did not indicate a carcinogenic
							potential for Sectral. Diacetolol, the major metabolite of Sectral in
							man, was without carcinogenic potential in rats when tested at doses as
							high as 1800 mg/kg/day. Sectral and diacetolol were also shown to be
							devoid of mutagenic potential in the Ames Test. Sectral, administered
							orally to two generations of male and female rats at doses of up to 240
							mg/kg/day (equivalent to 12 times the maximum recommended therapeutic
							dose in a 60-kg human) and diacetolol, administered to two generations
							of male and female rats at doses of up to 1000 mg/kg/day, had no
							significant impact on reproductive performance or fertility.
						</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-10"></a><p></p>
<h1><span class="Bold">Pregnancy</span></h1>
<div class="Section" data-sectionCode="34077-8">
<a name="section-10.1"></a><p></p>
<h2 class="Italics">Teratogenic Effects</h2>
<p class="First"> Pregnancy Category B: Reproduction studies have been
									performed with Sectral in rats (up to 630 mg/kg/day) and rabbits
									(up to 135 mg/kg/day). These doses are equivalent to
									approximately 31.5 and 6.8 times the maximum recommended
									therapeutic dose in a 60-kg human, respectively. The compound
									was not teratogenic in either species. In the rabbit, however,
									doses of 135 mg/kg/day caused slight <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span>;
									this effect was considered to be a result of maternal toxicity,
									as evidenced by reduced food intake, a lowered rate of body
									<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and mortality. Studies have also been performed in
									these species with diacetolol (at doses of up to 450 mg/kg/day
									in rabbits and up to 1800 mg/kg/day in rats). Other than a
									significant elevation in postimplantation loss with 450
									mg/kg/day diacetolol, a level at which food consumption and body
									<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were reduced in rabbit dams and a nonstatistically
									significant increase in incidence of bilateral <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> in rat
									fetuses from dams treated with 1800 mg/kg/day diacetolol, there
									was no evidence of harm to the fetus. There are no adequate and
									well-controlled trials in pregnant women. Because animal
									teratology studies are not always predictive of the human
									response, Sectral should be used during pregnancy only if the
									potential benefit justifies the risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-10.2"></a><p></p>
<h2 class="Italcs">Nonteratogenic Effects</h2>
<p class="First"> Studies in humans have shown that both acebutolol and
									diacetolol cross the placenta. Neonates of mothers who have
									received acebutolol during pregnancy have reduced birth weight,
									decreased blood pressure, and decreased heart rate. In the
									newborn the elimination half-life of acebutolol was 6 to 14
									hours, while the half-life of diacetolol was 24 to 30 hours for
									the first 24 hours after birth, followed by a half-life of 12 to
									16 hours. Adequate facilities for monitoring these infants at
									birth should be available. </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-11"></a><p></p>
<h1><span class="Bold">Labor and Delivery</span></h1>
<p class="First"> The effect of Sectral on labor and delivery in pregnant women is
							unknown. Studies in animals have not shown any effect of Sectral on the
							usual course of labor and delivery. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-12"></a><p></p>
<h1><span class="Bold">Nursing Mothers</span></h1>
<p class="First"> Acebutolol and diacetolol also appear in breast milk with a
							milk:plasma ratio of 7.1 and 12.2, respectively. Use in nursing mothers
							is not recommended. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-13"></a><p></p>
<h1><span class="Bold">Pediatric Use</span></h1>
<p class="First"> Safety and effectiveness in pediatric patients have not been
							established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-14"></a><p></p>
<h1><span class="Bold">Geriatric Use</span></h1>
<p class="First"> Clinical studies of Sectral and other reported clinical
							experience is inadequate to determine whether there are differences in
							safety or effectiveness between patients above or below age 65. </p>
<p> Elderly subjects evidence greater bioavailability of acebutolol
							(see <span class="Bold"><a href="#PKandMetabolism">CLINICAL
									PHARMACOLOGY—Pharmacokinetics and Metabolism</a></span>), presumably because of age-related reduction in first-pass
							metabolism and renal function. Therefore, it may be appropriate to start
							elderly patients at the low end of the dosing range (see <span class="Bold"><a href="#Useinolderpts">DOSAGE AND ADMINISTRATION—Use in
									Older Patients</a></span>). </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-15"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"> Sectral is well tolerated in properly selected patients. Most
							adverse reactions have been mild, not required discontinuation of
							therapy, and tended to decrease as duration of treatment increases. </p>
<p> The following table shows the frequency of treatment-related
							side effects derived from controlled clinical trials in patients with
							<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. These patients received
							Sectral, propranolol, or hydrochlorothiazide as monotherapy, or placebo. </p>
<table>
<thead>
<tr class="First"><th colspan="5">TOTAL VOLUNTEERED AND ELICITED (U.S.
									STUDIES)</th></tr>
<tr class="Last">
<th align="left">Body System/<br>Adverse Reaction</th>
<th class="Botrule">SECTRAL<br>(N=1002)<br>%</th>
<th class="Botrule">Propranolol<br>(N=424)<br>%</th>
<th class="Botrule">Hydrochloro-<br>thiazide<br>(N=178)<br>%</th>
<th class="Botrule">Placebo<br>(N=314)<br>%</th>
</tr>
</thead>
<tbody>
<tr class="First"><td class="Italics">Cardiovascular</td></tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>1</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>1</td>
</tr>
<tr><td class="Italics">Central Nervous System</td></tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>1</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td>6</td>
<td>7</td>
<td>12</td>
<td>2</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td>11</td>
<td>17</td>
<td>10</td>
<td>4</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td>6</td>
<td>9</td>
<td>13</td>
<td>4</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td>3</td>
<td>6</td>
<td>5</td>
<td>1</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr><td class="Italics">Dermatologic</td></tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>1</td>
</tr>
<tr><td class="Italics">  Gastrointestinal</td></tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td>4</td>
<td>2</td>
<td>7</td>
<td>0</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>1</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td>4</td>
<td>6</td>
<td>3</td>
<td>1</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td>3</td>
<td>4</td>
<td>7</td>
<td>1</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td>4</td>
<td>6</td>
<td>3</td>
<td>0</td>
</tr>
<tr><td class="Italics">Genitourinary</td></tr>
<tr align="center">
<td align="left">  Micturition<br>(frequency)</td>
<td>3</td>
<td>1</td>
<td>9</td>
<td>&lt;1</td>
</tr>
<tr><td class="Italics">Musculoskeletal</td></tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>2</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>0</td>
</tr>
<tr><td class="Italics">Respiratory</td></tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td>4</td>
<td>6</td>
<td>4</td>
<td>2</td>
</tr>
<tr align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>&lt;1</td>
</tr>
<tr><td class="Italics">Special Senses</td></tr>
<tr class="Last" align="center">
<td align="left">  <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal Vision</span></td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>
<p> The following selected (potentially important) side effects were
							seen in up to 2% of Sectral patients:</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>,
							<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>,
							hyper/<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.</p>
<p><span class="Italics">Dermatological:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>,
							<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.<br></p>
<p><span class="Italics">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>.</p>
<p><span class="Italics">Liver and Biliary System:</span> A small
							number of cases of liver abnormalities (increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, LDH) have
							been reported in association with acebutolol therapy. In some cases
							increased bilirubin or alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, dark urine,
							<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and/or other symptoms have been reported. In
							some of the reported cases, the symptoms and signs were confirmed by
							rechallenge with acebutolol. The abnormalities were reversible upon
							cessation of acebutolol therapy.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, joint
							<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>,
							<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>. </p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>,
							<span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>.</p>
<p><span class="Italics">Autoimmune:</span> In extremely rare
							instances, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported. </p>
<p> The incidence of drug-related adverse effects (volunteered and
							solicited) according to Sectral dose is shown below. (Data from 266
							hypertensive patients treated for 3 months on a constant dose.) </p>
<table>
<thead><tr class="First Last">
<th align="left">Body System</th>
<th>400 mg/day<br>(N=132)</th>
<th>800 mg/day<br>(N=63)</th>
<th>1200 mg/day<br>(N=71)</th>
</tr></thead>
<tbody>
<tr class="First" align="center">
<td align="left">Cardiovascular</td>
<td>5%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr align="center">
<td align="left">Gastrointestinal</td>
<td>3%</td>
<td>3%</td>
<td>7%</td>
</tr>
<tr align="center">
<td align="left">Musculoskeletal</td>
<td>2%</td>
<td>3%</td>
<td>4%</td>
</tr>
<tr align="center">
<td align="left">Central Nervous System</td>
<td>9%</td>
<td>13%</td>
<td>17%</td>
</tr>
<tr align="center">
<td align="left">Respiratory</td>
<td>1%</td>
<td>5%</td>
<td>6%</td>
</tr>
<tr align="center">
<td align="left">Skin</td>
<td>1%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr align="center">
<td align="left">Special Senses</td>
<td>2%</td>
<td>2%</td>
<td>6%</td>
</tr>
<tr class="Last" align="center">
<td align="left">Genitourinary</td>
<td>2%</td>
<td>3%</td>
<td>1%</td>
</tr>
</tbody>
</table>
<div class="Section">
<a name="section-15.1"></a><p></p>
<h2><span class="Bold">Potential Adverse Events</span></h2>
<p class="First"> In addition, certain adverse effects not listed above
									have been reported with other β-blocking agents and
									should also be considered as potential adverse effects of
									Sectral. </p>
<p><span class="Italics">Central Nervous
									System</span>: Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to
									<span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span> (an acute syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for
									time and place), short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>,
									slightly clouded sensorium, and decreased performance
									(neuropsychometrics). </p>
<p><span class="Italics">Cardiovascula</span>r:
									Intensification of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (see <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span>). </p>
<p><span class="Italics">Allergic:</span> Erythematous
									<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>,
									and <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>. </p>
<p><span class="Italics">Hematologic:</span>
									<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, nonthrombocytopenic, and thrombocytopenic
									<span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>. </p>
<p><span class="Italics">Gastrointestinal:</span>
									Mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span> and <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>. </p>
<p><span class="Italics">Miscellaneous:</span> Reversible
									<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and Peyronie’s disease. The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span>
									associated with the β-blocker practolol has not been
									reported with Sectral during investigational use and extensive
									foreign clinical experience. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Overdosage"></a><a name="section-16"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"> No specific information on emergency treatment of overdosage is
							available for Sectral. However, overdosage with other
							β-blocking agents has been accompanied by extreme <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>,
							advanced <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, intraventricular conduction defects,
							<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and in
							susceptible patients, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Although specific
							information on the emergency treatment of Sectral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is not
							available, on the basis of the pharmacological actions and the
							observations in treating <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with other β-blockers, the
							following general measures should be considered:<br></p>
<ol>
<li>Empty stomach by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or lavage.</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>: IV atropine (1 to 3 mg in divided doses). If
								antivagal response is inadequate, administer isoproterenol
								cautiously since larger than usual doses of isoproterenol may be
								required. </li>
<li>Persistent <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in spite of correction of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>:
								Administer vasopressor (e.g., epinephrine, levarterenol, dopamine,
								or dobutamine) with frequent monitoring of blood pressure and pulse
								rate. </li>
<li><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>: A theophylline derivative, such as aminophylline
								and/or parenteral β<span class="Sub">2</span>-stimulant, such as
								terbutaline. </li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span>: Digitalize the patient and/or administer a
								diuretic. It has been reported that glucagon is useful in this
								situation. </li>
</ol>
<p>Sectral is dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-17"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section">
<a name="section-17.1"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></h2>
<p class="First"> The initial dosage of Sectral in uncomplicated
									mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is 400 mg. This can be given as a
									single daily dose, but in occasional patients twice daily dosing
									may be required for adequate 24-hour blood-pressure control. An
									optimal response is usually achieved with dosages of 400 to 800
									mg per day, although some patients have been maintained on as
									little as 200 mg per day. Patients with more severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>
									or who have demonstrated inadequate control may respond to a
									total of 1200 mg daily (administered b.i.d.), or to the addition
									of a second antihypertensive agent. Beta-1 selectivity
									diminishes as dosage is increased. </p>
</div>
<div class="Section">
<a name="section-17.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span></span></h2>
<p class="First"> The usual initial dose of Sectral is 400 mg daily given
									as 200 mg b.i.d. Dosage should be increased gradually until an
									optimal clinical response is obtained, generally at 600 to 1200
									mg per day. If treatment is to be discontinued, the dosage
									should be reduced gradually over a period of about two weeks.
								</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-17.3"></a><p></p>
<div class="Section">
<a name="Useinolderpts"></a><a name="section-17.3.1"></a><p></p>
<h3><span class="Bold">Use in Older Patients</span></h3>
<p class="First"> Older patients have an approximately 2-fold
											increase in bioavailability and may require lower
											maintenance doses. Doses above 800 mg/day should be
											avoided in the elderly. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-18"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"> Sectral<span class="Sup">®</span> (acebutolol HCl) is available in
							the following dosage strengths: </p>
<p> 200 mg, opaque purple and orange capsule marked "RP 700" and
								"Sectral<span class="Sup">®</span> 200"<br>NDC 67857-700-01, in bottles
							of 100 capsules. </p>
<p> 400 mg, opaque brown and orange capsule marked "RP 701" and
								"Sectral<span class="Sup">®</span> 400"<br> NDC 67857-701-01, in bottles
							of 100 capsules. </p>
<p class="Bold"> Keep tightly closed<br> Store at controlled
							room temperature 20° to 25°C (68° to 77°F)<br> Protect from light<br>
							Dispense in a light-resistant, tight container<br> Use carton to
							protect contents from light </p>
<p>Distributed by:<br>Promius Pharma, LLC<br> Bridgewater, NJ 08807 </p>
<p>Manufactured by:<br>
							PATHEON, Puerto Rico, Inc.
							<br> Manatí, Puerto Rico 00674, USA</p>
<p>Revised April 2008 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC-67857-700-01 100 Capsules	</p>
<p>SECTRAL®</p>
<p>(acebutolol HCL)</p>
<p>equivalent to<br>200 mg<br>acebutolol</p>
<p>SEALED FOR YOUR PROTECTION</p>
<p>Rx only</p>
<p>PROMIUS PHARMA</p>
<p><img alt="image of 200 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7eee95bf-0452-4d6e-9712-33403768695a&amp;name=sectral-200mg-100ct-display-panel.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SECTRAL 		
					</strong><br><span class="contentTableReg">acebutolol hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67857-700</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ACEBUTOLOL HYDROCHLORIDE</strong> (ACEBUTOLOL) </td>
<td class="formItem">ACEBUTOLOL</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Red No. 22</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Red No. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE (Purple) , ORANGE (Orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RP;700;Sectral;200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67857-700-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018917</td>
<td class="formItem">12/28/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SECTRAL 		
					</strong><br><span class="contentTableReg">acebutolol hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67857-701</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ACEBUTOLOL HYDROCHLORIDE</strong> (ACEBUTOLOL) </td>
<td class="formItem">ACEBUTOLOL</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Red No. 22</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Brown) , ORANGE (Orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">24mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RP;700;Sectral;400</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67857-701-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018917</td>
<td class="formItem">12/28/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Promius Pharma, LLC
							(020408265)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Promius Pharma, LLC (020408265)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Puerto Rico, Inc.</td>
<td class="formItem"></td>
<td class="formItem">143814544</td>
<td class="formItem">manufacture(67857-700, 67857-701)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8d674ec6-61e4-41f2-91f8-4a0df9c141b9</div>
<div>Set id: 7eee95bf-0452-4d6e-9712-33403768695a</div>
<div>Version: 1</div>
<div>Effective Time: 20120112</div>
</div>
</div> <div class="DistributorName">Promius Pharma, LLC</div></p>
</body></html>
